IP Library Patent Application 12260794
Patent Application
App. No. 12/260,794

NUTRITIONAL SUPPLEMENTS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
12/260,794
Abstract

The present disclosure relates to novel nutritional methods and compositions containing essential fatty acids which optimize embryonic, fetal and child neurological development and provides improved nutritional support for women prior to and during lactation. Further the methods and compositions improve gestational length and birth weight. The nutritional methods and compositions are also intended for use by women to optimize infant neurological development and provide improved nutritional support for women prior to, during and after lactation.

Claims (16)

1 . A composition for supplementing the diet, the composition comprising:

a. a first fatty acid; and

b. DHA present in a quantity such that the total amount of said first fatty acid and said DHA is from about 10 mg to about 1000 mg.

2 . A composition for administration to a pregnant or lactating woman, the composition comprising:

a. a first fatty acid; and

b. DHA present in a quantity such that the total amount of said first fatty acid and said DHA is from about 10 mg to about 1000 mg.

3 . A method for administering essential fatty acids, which comprises:

a. administering a first fatty acid; and

b. administering DHA present in a quantity such that the total amount of said first fatty acid and said DHA is from about 10 mg to about 1000 mg.

4 . A method for administering essential fatty acids to pregnant or lactating women, which comprises:

a. administering a first fatty acid; and

b. administering DHA present in a quantity such that the total amount of said first fatty acid and said DHA is from about 10 mg to about 1000 mg.

5 . The composition of claim 1 , wherein the ratio of the amount of said first fatty acid to said DHA is from about 1:0.001 to about 1:50.

6 . The composition of claim 2 , wherein the ratio of the amount of said first fatty acid to said DHA is from about 1:0.001 to about 1:50.

7 . The method of claim 3 , wherein the ratio of the amount of said first fatty acid to said DHA is from about 1:0.001 to about 1:50.

8 . The method of claim 4 , wherein the ratio of the amount of said first fatty acid to said DHA is from about 1:0.001 to about 1:50.

Assignments (4)
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025980/0024 →
RELEASE OF SECURITY INTEREST Recorded Mar 18, 2011
From: U.S. HEALTHCARE I, LLC (AS ADMINISTRATIVE AND COLLATERAL AGENT)
To: DRUGTECH CORPORATION
Reel/Frame 025981/0934 →
PATENT SECURITY AGREEMENT Recorded Nov 20, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, LLC
Reel/Frame 025385/0498 →
PATENT SECURITY AGREEMENT Recorded Sep 14, 2010
From: DRUGTECH CORPORATION
To: U.S. HEALTHCARE I, L.L.C.
Reel/Frame 024982/0344 →